Nektar Therapeutics (NASDAQ: NKTR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -8.42 | Insider Own | - | Shs Outstand | 19.54M | Perf Week | -0.07% |
| Market Cap | 1.38B | Forward P/E | - | EPS next Y | -10.77 | Insider Trans | -0.14% | Shs Float | 18.33M | Perf Month | 9.75% |
| Enterprise Value | 1.39B | PEG | 6.83 | EPS next Q | - | Inst Own | - | Short Float | 37.21% | Perf Quarter | -16.90% |
| Income | -124.84M | P/S | 24.82 | EPS this Y | -6.30% | Inst Trans | - | Short Ratio | 5.86 | Perf Half Y | 100.60% |
| Sales | 55.63M | P/B | 3.03 | EPS next Y | -20.31% | ROA | -20.71% | Short Interest | 6.82M | Perf YTD | 67.15% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -87.00% | 52W High | 108.88 -35.17% | Perf Year | 220.21% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -17.17% | 52W Low | 21.00 236.20% | Perf 3Y | 772.47% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -15.76% -18.50% | Gross Margin | 99.38% | Volatility | 4.73% 5.30% | Perf 5Y | -71.46% |
| Dividend TTM | - | EV/Sales | 25.03 | EPS Y/Y TTM | 3.00% | Oper. Margin | -224.88% | ATR (14) | 3.57 | Perf 10Y | -69.39% |
| Dividend Ex-Date | - | Quick Ratio | 10.21 | Sales Y/Y TTM | -42.86% | Profit Margin | -284.18% | RSI (14) | 54.50 | Recom | 2.48 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.21 | EPS Q/Q | 44.85% | SMA20 | 0.95% | Beta | 1.15 | Target Price | 150.17 |
| Payout | 0.00% | Debt/Eq | 0.25 | Sales Q/Q | 10.00% | SMA50 | 7.43% | Rel Volume | 0.50 | Prev Close | 70.67 |
| Employees | 63 | LT Debt/Eq | 1.42 | Earnings | Aug 13 | SMA200 | 12.13% | Avg Volume | 998.90K | Price | 70.59 |
| IPO Date | May 03, 1994 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -15.02% 1.59% | Net Debt/EBITDA | -0.09 | Volume | 497,119 | Change | -0.11% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-22-26 | Initiated | Canaccord | Buy | $153 |
| May-11-26 | Reiterated | Wedbush | Neutral | $95 → $80 |
| May-08-26 | Reiterated | Piper Sandler | Overweight | $105 → $192 |
| Apr-21-26 | Reiterated | Wedbush | Neutral | $95 |
| Apr-20-26 | Reiterated | HC Wainwright & Co. | Buy | $165 → $185 |
| Mar-13-26 | Reiterated | Oppenheimer | Outperform | $115 → $140 |
| Feb-10-26 | Reiterated | BTIG | Buy | $151 |
| Feb-10-26 | Reiterated | HC Wainwright & Co. | Buy | $135 → $165 |
| Jan-26-26 | Reiterated | Piper Sandler | Overweight | $105 |
| Dec-16-25 | Reiterated | Oppenheimer | Outperform | $98 → $115 |
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 56 | 55 | 98 | 90 | 92 | 102 | 153 | 115 | 1,193 | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 31 | 37 | 22 | 25 | 19 | 21 | 24 | |
| Gross Profit | 56 | 55 | 68 | 53 | 70 | 77 | 133 | 93 | 1,169 | |
| Selling, General and Administrative Excl. Other | 57 | 69 | 77 | 77 | 92 | 123 | 105 | 99 | 81 | |
| Research and Development | 123 | 117 | 121 | 114 | 218 | 400 | 409 | 435 | 400 | |
| Other Operating Expense | 0 | 0 | -25 | 0 | 1 | 0 | -1 | -1 | 0 | |
| Operating Income | -125 | -131 | -105 | -137 | -240 | -446 | -380 | -440 | 688 | |
| Interest Expense | 29 | 26 | 28 | 25 | 29 | 47 | 37 | 46 | 43 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -4 | -7 | 14 | -113 | -96 | -30 | -27 | 46 | 38 | |
| Net Income Before Taxes | -159 | -164 | -119 | -276 | -365 | -523 | -444 | -440 | 683 | |
| Income Taxes | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 1 | 1 | |
| Consolidated Net Income | -159 | -164 | -119 | -276 | -368 | -524 | -444 | -441 | 681 | |
| Net Income From Continuing Operations | -159 | -164 | -119 | -276 | -368 | -524 | -444 | -441 | 681 | |
| Net Income | -159 | -164 | -119 | -276 | -368 | -524 | -444 | -441 | 681 | |
| EPS (Recurring) | -8.42 | -9.73 | -8.68 | -21.79 | -29.51 | -42.90 | -37.33 | -37.80 | 56.70 | |
| EPS (Basic, Before Extraordinaries) | -8.42 | -9.73 | -8.68 | -21.79 | -29.51 | -42.90 | -37.33 | -37.80 | 56.70 | |
| EPS (Diluted) | -8.42 | -9.73 | -8.68 | -21.79 | -29.51 | -42.90 | -37.33 | -37.80 | 56.70 | |
| EBITDA | -126 | -137 | -87 | -243 | -324 | -462 | -394 | -383 | 734 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | 8.70 | |
| Price To Sales Ratio | 31.51 | 13.07 | 1.99 | 1.22 | 4.42 | 23.84 | 20.00 | 33.79 | 4.96 | |
| Gross Margin | 100.00 | 100.00 | 69.39 | 58.89 | 76.09 | 75.49 | 86.93 | 80.87 | 97.99 | |
| Operating Margin | -223.21 | -238.18 | -107.14 | -152.22 | -260.87 | -437.25 | -248.37 | -382.61 | 57.67 | |
| Net Margin | -283.93 | -298.18 | -121.43 | -306.67 | -400.00 | -513.73 | -290.20 | -383.48 | 57.08 | |
| Shares Outstanding | 25 | 17 | 14 | 13 | 12 | 12 | 12 | 12 | 12 | |
| Market Capitalization | 1,765 | 719 | 195 | 110 | 407 | 2,432 | 3,060 | 3,886 | 5,917 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan | Chief R&D Officer | Jun 30 '26 | Sale | 70.00 | 5,681 | 397,670 | 9,756 | Jul 02 |
| ROBIN HOWARD W | President & CEO | Jun 17 '26 | Sale | 61.19 | 10,000 | 611,880 | 55,045 | Jun 18 |
| ROBIN HOWARD W | President & CEO | Jun 16 '26 | Sale | 60.32 | 10,000 | 603,176 | 65,045 | Jun 18 |
| Zalevsky Jonathan | Chief R&D Officer | Jun 15 '26 | Sale | 60.71 | 5,538 | 336,212 | 15,437 | Jun 17 |
| ROBIN HOWARD W | President & CEO | May 19 '26 | Sale | 65.51 | 444 | 29,086 | 75,045 | May 21 |
| Zalevsky Jonathan | Chief R&D Officer | May 19 '26 | Sale | 65.51 | 199 | 13,036 | 20,975 | May 21 |
| Zalevsky Jonathan | Chief R&D Officer | Feb 18 '26 | Sale | 73.00 | 180 | 13,140 | 21,174 | Feb 20 |
| ROBIN HOWARD W | President & CEO | Feb 18 '26 | Sale | 73.00 | 423 | 30,879 | 75,489 | Feb 20 |
| Zalevsky Jonathan | Chief R&D Officer | Jan 20 '26 | Sale | 35.67 | 3,867 | 137,936 | 21,354 | Jan 22 |
| Wilson Mark Andrew | Chief Legal Officer | Nov 25 '25 | Sale | 54.28 | 630 | 34,196 | 21,585 | Nov 25 |
| ROBIN HOWARD W | President & CEO | Nov 25 '25 | Sale | 54.28 | 2,207 | 119,796 | 54,245 | Nov 25 |
| Zalevsky Jonathan | Chief R&D Officer | Nov 25 '25 | Sale | 54.28 | 1,157 | 62,802 | 18,971 | Nov 25 |
| ROBIN HOWARD W | President & CEO | Sep 09 '25 | Sale | 46.69 | 6,666 | 311,214 | 49,342 | Sep 11 |
| ROBIN HOWARD W | President & CEO | Sep 05 '25 | Sale | 38.53 | 6,666 | 256,850 | 56,008 | Sep 08 |
| ROBIN HOWARD W | President & CEO | Sep 04 '25 | Sale | 33.70 | 5,166 | 174,108 | 62,674 | Sep 08 |